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Introduction
Th irty-one years have passed since reports of severely 
immune-compromised gay men in San Francisco and 
New York ﬁ rst drew attention to the AIDS epidemic [1,2]. 
It took 3 years to identify the cause as human immuno-
deﬁ ciency virus (HIV)-1, a lentivirus that subverts the 
lymphoid system to become viral factories producing 1-
2 billion virions per day. HIV-1 infects and destroys CD4-
bearing lymphocytes, decreasing the victim’s ability to 
overcome normally innocuous agents such as Pneumo-
cystis, Candida, cytomegalovirus and a score of other 
opportunistic infections (Box  1). Left untreated, these 
infections and certain rare cancers contribute further to 
the immune system collapse and to the demise of the 
patients. An eﬀ ective vaccine is yet to be developed, and 
anti-retroviral drugs are not ideal since they do not work 
well for all patients, can generate adverse side eﬀ ects and 
do not eliminate the virus from an infected patient. Since 
the ﬁ rst reports of AIDS in 1981, the world has seen more 
than 60  million cases of HIV infections, and 30  million 
victims have died as a consequence, 90% of them in the 
developing world [3].
Th e genomic era began eleven years ago with the 
release of the draft sequence of the human genome. A 
complete human gene set and DNA sequence was avail-
able to help combat the more inscrutable deadly chronic 
and infectious diseases [4], and this has enabled the 
investi gation of HIV/AIDS using the new tools of 
genomics. AIDS exhibits abundant epidemiological 
hetero geneity, much of which could be attributed to host 
genetic factors. Beginning in the early 1980s, epidemio-
logists began collecting longitudinal cohorts of at-risk 
AIDS populations to describe that heterogeneity. Many 
collaborated with geneticists, who used population 
genetics-based association analyses to uncover genes 
with natural variants that exerted an eﬀ ect on HIV 
infection, on the dynamics of AIDS progression, and on 
the results of highly active anti-retroviral therapy 
(HAART). Th is review will attempt to update the status 
of discovered host genetic inﬂ uences on stages of AIDS 
beyond the informative reviews that have appeared to 
date [5-10]. We will highlight those host gene inﬂ uences 
that are credible, replicated and implicated in AIDS 
disease, and we will discuss their clinical relevance in 
stemming the spread of HIV .
Candidate AIDS restriction genes: the case of 
CCR5-Δ32
Before the ﬁ rst of ten HIV-AIDS genome-wide asso cia-
tion studies (GWAS) appeared [11], single nucleotide 
poly morphism (SNP) variants in numerous candidate 
genes were suggested as being associated with HIV or 
AIDS in patients. Several hundred candidate gene SNPs 
were tested for association with AIDS progression and 
for HIV transmission. Over 35 plausible AIDS restriction 
genes (ARGs) have been identiﬁ ed (Table  1). Th eir dis-
covery, replication and functional interpretation have 
been reviewed in depth, and these reviews should be 
con sulted to appreciate the details uncovered around 
each ARG discovery [5-10].
Th e ﬁ rst and perhaps most provocative ARG involved 
the description of CCR5-Δ32, a 32 base pair deletion 
frameshift mutation that truncates C-C chemokine 
receptor 5 (CCR5), the HIV entry receptor on lymphoid 
cells [12-14] (see Box 2 for a discussion of the origin of 
this mutation). Epidemiological studies showed that indi-
viduals homozygous for CCR5-Δ32 had a 100-fold reduc-
tion in HIV infection incidence: the genotype seems to 
confer near complete protection from HIV infection 
(Figure  1). Individuals in large cohort studies that are 
hetero zygous for CCR5-Δ32, although susceptible to 
infection, consistently have a delayed onset of AIDS by 
two to four years, likely due to the diminishing onset of 
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B-cell lymphoma [12,15]. Further, AIDS patients on 
HAART live longer when they are heterozygous for the 
CCR5-Δ32 mutation, due to faster HIV viral load sup-
pres sion, and progress to AIDS more slowly than CCR5+/+ 
patients on HAART (Figure 1c) [16]. It is clear that latent 
HIV continues its pathogenesis in these patients, even in 
the presence of eﬀective anti-retroviral treatment. We 
therefore need to develop better AIDS therapies.
CCR5 in clinical practice
Individuals homozygous for CCR5-Δ32 seem to be 
relatively healthy into advanced age, suggesting that 
Box 1. The stages of AIDS progression
AIDS is one of the most intensively studied diseases in history, providing not only a rich description of the steps in steady progression 
to immune collapse and death, but also discrete stages that can be investigated for host genetic influence. The process begins when 
a person becomes exposed to HIV-1, which can occur through sexual contact with an infected partner, intravenous injection with 
contaminated needles used to deliver addictive drugs, or receipt of contaminated blood or blood products (for example, clotting Factor 
VIII and IX in the case of hemophiliacs). Once an individual becomes infected, HIV-1 seeks out and overtakes CD4-bearing T-lymphocytes 
to produce a struggle between viral production (tracked as the viral load – the virus titer in circulating blood) and immune defenses that 
struggle to control viral proliferation in the beginning weeks. With more than 1 billion new HIV copies produced each day by an acutely 
infected person, and with new mutational variants arising at a rate of one every second virus copy, immune control is no mean feat. 
Nonetheless. in most infected people the viral load settles to a chronic plateau level, which varies among individuals from 1 x 103 to 1 x 105 
virions/ml (known as the viral set point). Over time the virus gradually destroys the CD4 lymphocytes and the blood count drops to below 
200 CD4+ cells/mm3. The time in which CD4 cell depletion occurs can vary from within a year of infection to more than 20 years later, with 
the mean time at approximately 10 years post infection. Once the CD4 cell counts drop, the patients succumb to a variety of normally 
innocuous infections (Candida, Pneumocystis carinii, cytomegalovirus, herpes, tuberculosis and others) and to rare cancers such as Kaposi’s 
sarcoma and B cell lymphomas. If left untreated, these infections and cancers almost invariably lead to death.
In 1996, a powerful triple drug anti-retroviral therapy was initiated and offered a milestone in AIDS treatment and prognosis. In most 
patients receiving this treatment, known as highly active anti-retroviral therapy (HAART), the viral load drops to below detectable levels. 
As promising as these treatments became, there were caveats. Many people (20 to 40%) do not tolerate the drugs and develop adverse 
reactions. The treatment does not clear HIV from many tissues, and suspension of treatment therefore invariably results in viral load 
rebound in the blood. Last, in spite of viral replication repression, there is still slow viral-induced pathology and so many patients continue, 
albeit more slowly, to progress to AIDS and death.
Genetic researchers noted epidemiological differences in four principal stages: (1) HIV acquisition of infection; (2) the rate of progression 
to AIDS among HIV-infected individuals; (3) the nature of the AIDS-defining condition displayed; and (4) the outcome of HAART, viral load 
suppression, adverse events and AIDS progression post-treatment [5-10] (Table 1). Case–control and survivor analyses (in the form of Cox 
proportional hazards models) parsed into alternative SNP alleles or genotypes allow for statistical comparison for differences in patient 
populations that exhibit better or worse outcome for each stage, leading to gene/SNP association.
Source: An and Winkler [5], reproduced with permission.
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Table 1. Candidate AIDS restriction genes
Year Gene symbol Allele Mode Effect Citation(s)
1996 CCR5 Δ32 Recessive Prevents infection  [12-14]
1996 CCR5 Δ32 Dominant Delays AIDS [12]
1997 CCR2 64I Dominant Delays AIDS [80]
1998 CCR5P P1 Recessive Accelerates AIDS [81]
1998 SDF1 3’A Recessive Delays AIDS [82]
1999 CCR5 Δ32 Dominant Prevents lymphoma [15]
1999 HLA A,B,C,’Homozy’ Co-dominant Accelerates AIDS [83]
2000 IL10 5’A Dominant Limits infection [84]
 IL10 5’A Dominant Accelerates AIDS [84]
2001 HLA B*35Px Co-dominant Accelerates AIDS [85]
2002 RANTES –403A Dominant Accelerates AIDS [86]
  In1.1C Co-dominant Accelerates AIDS [86]
2002 KIR 3DS1 Epistatic Delays AIDS [28,29]
   (Bw4-801)  
2003 EOTAXIN-MCP1 Hap7 Dominant Enhances infection [87]
2003 HLA B*57 Co-dominant Delays AIDS [88]
2003 IFNG 179T Dominant Accelerates AIDS [89]
2003 CXCR6 E3K Dominant Accelerates PCP [90]
2004 APOBEC3G H186R Recessive Accelerates AIDS [91]
2004 DCSIGN –336T Dominant Decreases infection [92]
2006 HLA B27 Co-dominant Delays AIDS [93]
2006 TSG101 Hap2 Dominant Accelerates AIDS [94]
2006 TRIM5 Hap4 Dominant Increases infection [95]
2007 CUL5 HapI Co-dominant Accelerates CD4 loss [96]
2007 PP1A (cyclophilin A) SNP-4 Dominant Accelerates AIDS [97]
2007 HLA Bw4 Dominant Reduces HIV [98]
    Transmission 
2008 MYH9   End Stage Renal Disease [31]
2008 MYH9   HIV FSGN [30]
2008 mtDNA Hap-J, U5a Dominant Accelerates AIDS [56]
2008 mtDNA Hap-H Dominant Increases [55]
    Lipoatrophy post 
    HAART 
2008 mtDNA Hap-J Dominant Delays CMV-NRD [99]
2009 HCP5 T>G; rs2395029 Dominant HIV set point [33]
2009 HLA rs9264942 Dominant HIV set point [33]
2009 PROX1 Hap-CGT Recessive Delays AIDS progression [37]
2009 APOBEC 3B ΔV_ Recessive Increases infection [100]
2010 PECI G Dominant Accelerates AIDS [52]
2010 ACSM4 A Co-dominant Delays AIDS [52]
2010 NCOR2 T Dominant Increases infection [57]
2010 IDH1 C Dominant Prevents infection [57]
All these genes were discovered or validated using the NCI-Laboratory of Genomic Diversity. Eight AIDS cohorts comprising more than 10,000 study participants were 
used in these studies from 1985 to 2011 [5,10,79,101].
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CCR5 function is dispensable in the human genome, a 
notion supported by the redundancy of other human 
chemo kine receptors that also interact with speciﬁc 
chemo kine ligands of CCR5 [17]. The knowledge that 
CCR5 is required for HIV-1 infection of lymphoid cells in 
exposed people, plus the suspicion that CCR5 function is 
dispensable for good health [18] (see Box 3), stimulated 
pharmaceutical development of a dozen new anti-AIDS 
treatments termed HIV entry inhibitors. Entry inhibitors 
were designed to interfere with HIV–CCR5 cell receptor 
binding as a block to HIV pathogenesis [19-21]. Two 
power ful HIV entry inhibitors, enfuviritude (T20) and 
maraviroc, were approved for AIDS patient treatment by 
the Food and Drug Administration (FDA) in 2003 and 
2007, respectively. The rapid development of this new 
avenue for AIDS therapy was clearly encouraged by the 
characterization of HIV resistance in CCR5-Δ32 homo-
zygotes (the 30-plus other HAART drugs all target HIV-
encoded enzymes: reverse transcriptase  – targeted by 
both nucleotide reverse transcriptase inhibitors and non-
nucleoside reverse transcriptase inhibitors  – and the 
HIV-encoded protease).
A remarkable example of CCR5-Δ32 clinical translation 
to the bedside involves the treatment of Timothy Leigh 
Brown, dubbed the ‘Berlin patient’ [22]. Brown was a 
25-year-old American living in Berlin in 1995 when he 
was diagnosed with HIV infection. Despite receiving 
sporadic anti-HIV medication, his condition deteriorated 
and he was diagnosed with acute myelogenous leukemia 
in 2006. His AIDS clinician, Gero Hutter, prescribed a 
stem cell transplant of healthy HIV-negative donor 
lympho cytes following x-irradiation of his lymphoid 
system [23]. Hutter searched the European bone marrow 
databases to ﬁnd an HLA-matched donor who was 
homo zygous for CCR5-Δ32, so as to block HIV trans-
mission to the donor graft cells. After the stem cell trans-
plant in February 2007, Brown’s anti-retroviral treatment 
was suspended to allow the graft to grow, though 
monthly blood tests were initiated to detect the inevitable 
latent HIV rebound. But rebound never occurred. 
Three  years later, Hutter and his team reported that 
Brown had consistently tested negative for circulating 
plasma HIV since the transplant [23]. Subsequent rather 
invasive biopsies of multiple tissues (plasma, gut, brain, 
testis, liver) using hyper-sensitive virus assays were also 
negative, indicating that his body had been cleared of 
replicating HIV, the ﬁrst such event recorded in history 
[22-24]. Though no one is certain that each and every one 
of the scores of human tissues that can become infected 
with HIV are clear in Mr Brown’s body, as of now – ﬁve 
years later – his case is being heralded as the single docu-
mented clearance or apparent cure of HIV infection.
Bone marrow and stem cell transplants are of limited 
promise as a universal therapy. They are expensive (circa 
US$250,000) and not very safe, primarily because even 
HLA-matched donors are immunologically allogeneic 
(that is, non-self ). The immune system of the recipient 
must be destroyed, deadly graft versus host reaction 
against the host is common, and a dangerous trans-
planta tion therapy must be followed by a lifelong 
Box 2. The origins of the CCR5-Δ32 mutation in human populations
The CCR5-Δ32 allele occurs at a relatively high frequency in Europe (about 10%), but is completely absent in native African and Asian 
people. This distribution, plus the high incidence of amino acid-altering mutations (about 80%) among all SNP variants in the CCR5 
locus, lent support to the idea that CCR5-Δ32 was likely the object of strong selective pressures favoring CCR5-Δ32 frequency elevation in 
European ancestors [18,71,72]. The extended haplotype of SNPs around CCR5-Δ32 is about 1,000 kb, 100 times longer than the average 
haplotype size in Europeans, suggesting a recent mutational origin of CCR5-Δ32 and possibly a selective advantage of CCR5-Δ32 carriers 
[72-74].
But what was the selective pressure? It was likely a global deadly epidemic that CCR5-Δ32 carriers were resistant to, but it could not 
have been HIV/AIDS since this epidemic emerged in the early 20th century, too recent to account for the high frequency of CCR5-Δ32 in 
European populations. An evolutionary computation based upon the length of the extended CCR5 haplotype was used to estimate that 
the date of the latest selective elevation of CCR5-Δ32 was about 700 years ago [72]. This calculation raised the prospect that survivors of the 
Black Death (in which bubonic plague killed some 25,000,000 Europeans in 1348–1353 CE) had a role in favoring the elevation of CCR5-Δ32. 
A functional demonstration that cultured cells from Ccr5–/– knockout mice (equivalent to CCR5-Δ32/Δ32 homozygous people) show a 30-
fold reduction in sensitivity to infection by Yersinia pestis, the plague bacillus, compared with Ccr5+/+ normal mice [75] lends credence to 
this provocative explanation. A more detailed narrative of the still unproven plague hypothesis is presented in [76].
There are alternative interpretations as to the cause of CCR5-Δ32-selective elevation (some have proposed that anthrax, small pox, Ebola 
and other contagions played a selective role in the rise of CCR5-Δ32 in medieval Europe) and even for Black Death etiology. Whether 
the direction of the allele frequency cline (gradient) across Europe tracks the plague progression or whether plague mortality was large 
enough to elevate CCCR5-Δ32 sufficiently have been raised in critiques of the plague/CCR5-Δ32 hypothesis. Nonetheless, the functional 
connection of a CCR5 receptor requirement for Yersinia infection, the coalescent date of 700 years for CCR5-Δ32 haplotype origins, the 
enormous toll of the Black Death (an estimated 25 million Europeans – one-third of the population – perished by the Black Death) and 
the multiple plague episodes across Europe tracing from the Justinian plague (541 to 542 CE) to the 17th-century Great Plague of London 
(1664 to 1666 CE) all lend support to plague being a principal selective pressure on CCR5-Δ32 [18,72,76].
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regimen of anti-rejection therapies. A promising alterna-
tive to this may be immunologically syngeneic (self ) 
grafts with CCR5 knockout strategies. Carl June and 
Bruce Levine at University of Pennsylvania have developed 
such a proto col using zinc ﬁnger targeted knockout of 
normal CCR5 genes in HIV-infected patients [25]. Twelve 
such patients have been infused with their own-engi-
neered CCR5–/– lymphocytes. The results are promising 
to date, with donor cell reconstitution observed and few 
safety issues encountered, and several patients remained 
plasma HIV-negative several months post transplant 
infusion.
News of the Berlin patient’s amazing recovery travelled 
quickly in the AIDS research community and beyond. 
Attention was also paid to the fascinating secondary 
observation that the Berlin patient has never developed 
graft versus host disease (GVHD), a deadly reaction that 
aﬄicts 30–50% of bone marrow and stem transplant 
recipients. Transplant researchers at University of 
Pennsyl vania reasoned that perhaps the CCR5-Δ32 
genotype of the Berlin patient’s transplant donor might 
have pre vented his GVHD; this would aﬃrm a role for 
intact CCR5 in GVHD. The availability of safe and FDA 
approved CCR5 antagonist drugs for AIDS, such as 
maraviroc, prompted a Phase I and II clinical trial to see 
if maraviroc-treated transplant patients might avoid 
GVHD, as with the Berlin patient [26]. A group of 38 
cancer patients treated with maraviroc post-transplant 
demonstrated a dramatic reduction in GVHD without 
any major adverse side eﬀects. If conﬁrmed by a larger 
Phase III trial, CCR5 may therefore be implicated as a key 
player in cancer treatments as well as AIDS therapies. It 
should be noted that maraviroc is considered to be a safe 
drug and that CCR5-Δ32/32 homozygotes are generally 
healthy. If such bold new therapies do prove eﬃcacious, 
they will stand upon the ﬁndings of the CCR5-Δ32/Δ32 
homozygotes’ genetic resistance to HIV acquisition and 
the apparent success with the Berlin patient.
Figure 1. Influence of CCR-Δ32 on different stages of HIV AIDS. (a) HIV transmission/acquisition. The frequency (percentage) of CCR-Δ32 
genotypes among HIV infected versus HIV uninfected people in cumulative AIDS cohorts (total n = 17,214 study participants) [12-14,79,101]. 
(b) AIDS progression in HIV-infected people. Kaplan–Meier survival curves comparing the rate of AIDS onset in CCR+/+ versus CCR5+/Δ32 [12,79,101]. 
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AIDS resistance genes beyond CCR5
Each of the genes listed in Table  1 has the potential to 
have a detailed narrative such as that described for 
CCR5-Δ32. For example, HLA allelic resistance and 
susceptibility to AIDS progression is well accepted, and 
at least one HLA genotype, HLAB*5701, seems to pre-
dispose carriers to a severe immunological disorder 
(fever, gastrointestinal and respiratory distress) when 
they are treated with the nucleoside reverse transcriptase 
HIV inhibitor abacavir [27]. HLA genotyping is now a 
pre requisite to abacavir prescription. Epistatic inter-
actions of HLA class I protein products and the killer 
immunoglobulin cluster KIR ligands (chr19] are power-
ful, but have not yet informed clinical practice [28,29].
SNP variants within loci that exert powerful anti-HIV 
restrictions in vitro and against other viruses (TRIM5, 
APOBEC, TSG101, CUL5) have shown modest eﬀects on 
AIDS progression in association studies (Table 1). Unlike 
CCR5-Δ32, which confers a complete loss of function 
mutation, the consequence of most other ARG SNP 
variants are limited by quantitative inﬂuences on gene 
action. An important predictive inﬂuence on HIV-asso-
cia ted nephropathy, particularly among African Americans, 
appears to be associated with multi-SNP haplotypes 
within the MYH9 (non-muscle myosin IIA) gene [30,31]. 
The risk alleles are quite common in African Americans 
but rare in European Caucasians, which explains a 
20-fold higher risk for HIV-associated nephropathy in 
African Americans. Taken together, combining func-
tional data that connects ARG variants directly to HIV 
pathology, robust statistical gene SNP associations and 
clinical translation has improved our understanding of 
diagnosis, pathogenesis, treatment and ablation of AIDS.
HIV/AIDS GWAS
Unlike association studies of candidate genes, GWAS 
scan the entire genome with hundreds of thousands (if 
not millions) of common human SNPs to discover 
genome regions that statistically associate with explicit 
AIDS endpoints in large cohort studies (Box 1). Fellay et 
al. [11] reported the ﬁrst AIDS GWAS in 2007. Their 
study tracked the HIV set point (mean plasma viral RNA 
level over several months once the immune system has 
settled to a steady state level after initial spikes in virus 
upon HIV infection; see Box  1) in 486 European AIDS 
patients from the Euro-Center for HIV/AIDS Vaccine 
Immunology (CHAVI) cohort that were genotyped with 
an Illumina 550,000 SNP array. Fellay et al. discovered 
three genome-wide signiﬁcant (after Bonferroni correc-
tion for multiple SNP tests; <9.3  ×  10–8) SNPs nested 
within the HLA complex, including a proxy-SNP in 
linkage disequilibrium (LD) HLA-B*5701, a known pro-
tec tive inﬂuence on AIDS progression. Since then ten 
additional GWAS using diﬀerent cohorts, and diﬀerent 
AIDS stages (phenotypes), arrays and numbers of SNPs, 
have appeared [32-41]. The combined GWAS have 
consis tently ﬁngered HLA SNPs, but agreed on little else.
Additional GWAS-based gene discoveries outside HLA 
appear robust, but they have seldom included the 
candidate genes listed in Table 1, nor have the implicated 
gene associations been replicated by independent studies. 
Further, the fraction of the epidemiological variance of 
AIDS progression that individual or combined GWAS 
discovered genes can explain falls between 10% and 20% 
for AIDS progression and far less for other stages of 
AIDS (for example, HIV acquisition, HAART outcomes, 
and so on) [10,11,40]. Rediscovering HLA and the low 
level of explanative variance were disappointing to the 
AIDS community given the promise of GWAS for resolv-
ing gene determinants in other complex diseases. The 
advantages of GWAS over candidate gene studies are well 
known: (1)  they can reveal genes we may not have con-
sidered since they survey the entire genome; (2)  the 
patterns of LD allow for haplotype-based closing in on 
Box 3. The mixed blessing of inheriting a CCR5-Δ32/Δ32 genotype
The evidence that CCR5-Δ32 was protective against AIDS, and also the object of historic selective events likely from infectious agents other 
than HIV in the distant past, has stimulated a search for other viruses that may co-opt CCR5 molecules as entry portals to human cells. 
One fascinating study using West Nile Virus (WNV) raises some troubling issues [77,78]. WNV, a mosquito-borne flavivirus that was first 
introduced into New York City in 1999, induces a fatal encephalitis in 20% of human infections. The agent has caused 17,000 infections 
and 700 encephalitis cases to date, and so far there is no effective vaccine or treatment. Philip Murphy’s group at the National Institutes 
of Health (NIH) were searching for other CCR5–virus interactions when they examined the WNV infection response of Ccr5–/– knockout 
mice compared with Ccr5+/+ mice [77]. WNV upregulated the expression of CCR5 in the central nervous system of infected mice and this 
was associated with a massive infusion of CD4+, CD8+, NK1.1 lymphocytes and macrophages, all expressing CCR5, into the central nervous 
system (CNS). Survival and recovery in normal mice was about 60%. However, when Ccr5–/– knockout mice (equivalent to CCR5-Δ32 
homozygotes) were infected there was little immune reaction and the infection was uniformly (100%) fatal, implicating CCR5 as a critical 
innate host defense against WNV in mice. Murphy’s group mounted a large genetic epidemiological association study of WNV-infected 
people and discovered that CCR5-Δ32/Δ32 homozygotes were elevated 4- to 13-fold among the fatal encephalitis cases relative to the 
survivors [78]. Clearly the intact CCR5 gene function exerts a critical defense in the face of WNV. The alternative AIDS resistance and WNV 
hypersensitivity poses a mixed blessing for homozygous carriers of CCR5-Δ32 and a stark reminder that genetic adaptation can come with 
a cost in a changing microbial environment.
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the causal or operative SNP variant; (3)  copy number 
variants can be resolved by SNP genotyping arrays; and 
(4)  subsets of gene families can be explored using SNP 
array data (see below). The disadvantages of GWAS are 
that there are no a priori assumptions about a possible 
connection to AIDS as there are for candidate genes; 
therefore, SNP association discovery must be comple-
mented with additional function-based implication.
The large number of SNPs interrogated requires 
statistical correction for multiple testing, and to avoid 
false positives the signiﬁcance threshold must be 
stringent. Yet mixed among the below-threshold SNPs 
are a few gems, such as those in CCR5 and KIR, whose 
presence in pathways associated with AIDS pathogenesis 
make them too good to miss (for instance, many ARGs in 
Table 1 are not revealed by GWAS). Finally, GWAS can-
not resolve rare causal variants (f <5%).
Goldstein has suggested that rare variants may account 
for undiscovered genetic inﬂuences on AIDS and other 
complex diseases [42,43], but these genetic variants 
would not be uncovered by GWAS. Although it is im-
possible to predict future discoveries with conﬁdence, 
the frequent occurrence of deadly infectious disease 
episodes in human history has clearly provided abundant 
selective pressures (possibly raising allele frequencies for 
CCR5-Δ32, HB-S, DUFFY, HLA and others) elevating 
many disease immune defense alleles above the ‘rare 
allele’ frequency. We also suggest that the study design of 
some of the previous AIDS GWAS might be improved by 
assessing clinical endpoint/phenotypes less variable than 
viral load, set point and CD4 cell trajectory. Although 
viral load/set point are valid predictors of AIDS progres-
sion on a course scale, in our cohorts the signal suﬀers 
somewhat from noise, and is also less continuous than 
survival analyses (using Cox proportional hazards analy-
ses for detecting ARGs that inﬂuence AIDS progression). 
Better approaches for resolving the true association 
signals that fall below genome-wide signiﬁcance thres-
hold are needed if we are to maximize the potential of 
AIDS GWAS, and will likely require the evaluation of 
gene associations from a variety of perspectives.
One recent example of a potentially ‘better approach’ is 
the recent GWAS that associated several SNPs within the 
large 1.1 Mbp PARD3B gene (chr2), a locus that regulates 
cell polarity in epithelial cells [40,44]. Nine of the 15 
lowest P-values in the GWAS fell in a short 5 kb LD block 
across a single PARD3B exon. One of the nine SNPs 
reached genome-wide signiﬁcance (P = 3.4 × 10–9), while 
the others fell just below that threshold. The basis for the 
association (Figure  2) demonstrates that the rare geno-
type (GG) for the SNP almost never progress to AIDS, 
while people that are heterozygous for this SNP progress 
markedly slower than those homozygous for the common 
allele (CC). Support for the gene association came from 
six angles: (1) a nearly identical eﬀect was observed among 
two distinct risk groups (hemophiliacs and gay men; 
Figure 2b,c); (2) the SNP association result was repli cated, 
albeit with a weaker statistical strength (P  =  0.03), in 
independent European cohorts; (3)  one of the associated 
SNPs is a predicted exon splicing en hancer; (4) a quanti-
tative measure of PARD3B splice products in lympho-
blastoid B-cell lines with alternative PARD3B genotypes 
revealed a dominant 30 to 40% reduction in PARD3B 
isoform transcripts; (5)  in the GWAS, PARD3B alleles 
explained 4.3% of the epidemio logical variance of AIDS 
progression, higher than any of the other candidate genes 
in Table  1 similarly assessed in the same cohorts; (6) 
PARD3B gene products are known to interact with SMAD 
proteins, signal transduction modu lators that mediate 
gene signaling, including through a direct interaction with 
HIV regulatory proteins [45]. Taken together, the cumu-
lative replication, HIV1 regu latory connection, trans-
cription inﬂuence and asso cia tion data on PARD3B oﬀers 
a plausible new genetic inﬂuence of AIDS progression.
Beyond GWAS: new approaches
The PARD3B study was intentionally limited to a single 
endpoint or phenotype (time of progression as deﬁned by 
the AIDS 1987 Centers for Disease Control) to avoid 
statistical penalties for multiple tests. Yet many diﬀerent 
gene association tests are possible with the rich clinical 
and genetic data we have collected across the years on 
these retrospective AIDS cohorts; indeed, many of these 
tests were performed and considered supportive in the 
previous candidate gene studies [7,10] (Table 1). In spite 
of the aversion to multiple test statistical correction 
penalties, there is information than can be gleaned from 
detailed clinical data that should be explored. Hutcheson 
et al. [7] described useful heat plots that allow one to 
inspect the pattern of genetic association across many 
tests, as well as across small regions of the genome in 
strong LD. The combination of multiple non-independent 
statistical signals is a challenge to interpret, but in cases 
of known genes, such as CCR5-Δ32, HLA and IL10, the 
patterns are illuminating. The heat plots also provide a 
derivative approach to public data sharing of GWAS 
results without the problem of violating the informed 
consent and privacy constraints set out by Institutional 
Review Boards, which often restrict open access to human 
cohort data [46]. For example, posting an un abridged 
table of GWAS results online (odds ratios, P-values and 
conﬁdence intervals), together with two-dimensional and 
three-dimensional visualization heat plots, would allow 
researchers to freely inspect the results of a published 
GWAS [40], in any genomic region they may discover in 
a diﬀerent cohort, for independent replication purposes – 
without viewing patients’ conﬁdential clinical or geno-
typic information.
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Now that ten AIDS GWAS have been completed 
[11,30-41], it is important to share and compare these 
data to maximize the discoveries and minimize Type  1 
(false positive) errors. Meta-analyses such as the Inter-
national HIV Acquisition Consortium and the HIV 
Controllers Consortium are important advances that 
should be encouraged [35,47]. Further, most of the pub-
lished studies with any statistical power involve European 
Caucasian patients. Newer cohorts in Africa and Asia 
would increase the chance of discovering adaptive 
variants that may have arisen in those ethnicities in 
recent centuries. Such cohort developments are ongoing 
with the CHAVI consortium [48], the Botswana Harvard 
Partnership [49] and the Chinese AIDS collaboration 
[50]. It is also important to expand interrogation of 
critical stages of HIV/AIDS by exome and whole genome 
sequence analyses to capture SNP variants that are not 
well represented in available genotyping arrays [51]. 
Whole genome sequencing will oﬀer an unabridged 
assessment of gene variants in these cohorts and will 
likely reveal additional host factors that regulate AIDS 
pathogenesis.
A compromise approach between the speciﬁcity of 
candidate gene screens and the stringency of GWAS 
statistical thresholds is to explore certain candidate gene 
subsets represented within GWAS. This strategy limits the 
considered SNPs to speciﬁc subsets of candidate genes and 
lowers the multiple SNP test threshold for genome-wide 
signiﬁcance. Hendrickson et al. [52] used this approach to 
explore the association of a group of human genes that are 
involved in mitochondrial metabo lism, named nuclear 
encoded mitochondrial proteins (NEMPs) [53]. Mitochon-
drial metabolism is relevant because AIDS pathogenesis 
clearly involves mitochon drial deterioration and cell death, 
because mitochondrial toxicity has been linked to several 
adverse events of HAART, and because mitochondrial 
haplotypes appear to be associated with diﬀerential 
survival to AIDS in longitudinal cohorts [54-56].
Two tested NEMP-encoding genes displayed signiﬁcant 
(corrected for all SNPs considered) genotypic inﬂuences 
Figure 2. Influence of PARD3B genotypes on progression to AIDS – 1987 [40]. (a) Kaplan–Meier survival curves comparing the rate of 
AIDS onset among alternative genotypes of PARD3B – SNP rs11884476, with 755 seroconverters. RH: relative hazard. (b) and (c) show the same 
association analyses separated by risk group (HIV-infected men who have sex with men (MSM) and HIV-infected hemophiliacs, respectively) 
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on AIDS progression: peroxisomal D3,D2-enoyl-CoA 
isomerase (PECI) on chromosome  6 and acyl-CoA syn-
the tase medium-chain family member  4 (ACSM4) on 
chromosome  12 (Table  1). The gene subset approach 
allowed the detection of gene associations that would 
have been discounted in an agnostic full GWAS since 
their P-values of association signiﬁcance (P = 6.5 × 10–6 
and 3.6  ×  10–6 for PECI and ACSM4, respectively) fall 
below a full GWAS P-value threshold.
Another GWAS subset explored was that of genes 
required for HIV infection of cultured human cells, 
termed HIV dependency factors (HDFs) [57]. In 2008, 
four siRNA-based in vitro studies were published that 
collectively identiﬁed several hundred HDF genes [58-
61]. Chinn et al. [57] identiﬁed 6,380 SNPs that occurred 
within 278 HDF genes and used a subset of the PARD3B 
GWAS study data [40] to test them for gene associations 
with HIV infection, AIDS progression and AIDS-deﬁning 
sequelae. SNP variants in two genes, NCOR2 (also known 
as SMRT) and IDH1, showed signiﬁcant associations with 
HIV infection, consistent with their selection from HDF 
genes. IDH1 was particularly notable, ﬁrst since its HDF 
status was one of a few replicated in independent HDF 
studies [58,59], and second because IDH1 can function as 
both a tumor suppressor (loss of isocitrate dehydrogenase 
1 (IDH1] function) and an oncogene in human glio-
blastomas and other neoplasms [62-64].
The zinc ﬁnger ribbon domain 1 (ZNRD1) gene 
(located within the HLA locus) was one of the most 
strongly associated variants with HIV set point and 
disease progression in several GWAS [11,33]. ZNRD1 
also appeared as a candidate gene in one HDF screen 
[58], while Chinn et al. [57] implicated this gene as being 
associated with both HIV acquisition and HIV pro-
gression. These multiple indications of AIDS inﬂuence 
using diﬀerent approaches (GWAS, set point and survival 
analyses) together make a strong case for the inﬂuence of 
the ZNRD1 genotype on HIV/AIDS.
Conclusions
Thirty years of genomics investigation of AIDS has pro-
duced some important ﬁndings that have improved 
understanding of the disease and informed attempts to 
stem its deadly pace. Many host genes that aﬀect AIDS 
have been postulated through candidate gene associa-
tions, GWAS, HDF analyses, molecular virology and 
other approaches. Many, but not all, of the implicated 
genes have been independently replicated by various 
approaches designed to overcome the statistical challenge 
posed by multiple tests (for example, CCR5-Δ32, HLA, 
KIR, IDH1, ZFNR1 and others). Most important, at least 
ﬁve discoveries have led to bedside translation: 
(1) develop ment of CCR5-Δ32-based HIV entry inhibitor 
therapy [20,21]; (2)  HLA-based pharmacogenomics 
screen ing for B*5701-mediated abacavir adverse events 
[27]; (3) clearing of HIV from the Berlin patient by a stem 
cell transplant from a CCR5-Δ32/Δ32 homozygous donor 
led to gene therapy trials of autologous CCR5-Δ32 
knockout in AIDS patients [22-24]; (4) use of the CCR5 
antagonist, maraviroc, as GVHD prophylaxis in cancer 
patients receiving marrow and stem cell transplants [26]; 
and (5)  IDH1 discoveries have stimulated the search for 
drugs that block the accumulation of 2-hydroxyglutarate 
for cancer [62-64]. These cancer-targeted pharma ceu-
ticals may well equally inform HIV/AIDS therapies in the 
future.
The disappointments of the ARG searches are several. 
The total number of ARGs described account for less 
than 10 to 15% of the variance in AIDS progression and 
far less for other AIDS-associated measures: namely HIV 
acquisition, HAART outcomes or speciﬁc AIDS-deﬁning 
conditions. This means that most of the determinants 
(whether genetic or non-genetic) are yet to be deter-
mined. The stringent statistical threshold for GWAS may 
force us to discount real variants that do not pass the 
genome-wide signiﬁcance level; we need to develop a 
solution to this conundrum. In addition, genotyping 
arrays used to date, which contain between 500,000 and 
1,000,000 SNPs, cover at best 10 to 15% of the variants in 
genes and gene regions that we want to interrogate, so we 
depend upon LD to detect the causal variants through 
inference. We are missing much of the common variation, 
especially that found outside of genes (such as in the 
recently described 4 million regulatory regions [65]), and 
nearly 100% of the rare variants. Finally, because present 
GWAS largely target European Caucasian ethnic groups, 
variants accumulated in other ethnicities have not been 
thoroughly screened.
The next generation of ARG GWAS will address and 
remedy these shortcomings as follows. Combined meta-
analyses, such as the International HIV Acquisition Con-
sor tium [35,47], will help aﬃrm the statistically uncertain 
discoveries that are robust. Subset analyses such as the 
HDF and NEMP groups described in this review will help 
here. In addition, better strategies for data sharing of 
large GWAS and association studies will go a long way to 
encourage independent inspection, replication and 
composite interpretations. Bigger genotyping arrays (for 
example, Illumina 2.5M Inﬁnium arrays) will increase 
coverage greatly. By far the most comprehensive approach, 
whole genome sequencing, will accomplish this ever 
better, but cost is still the limiting factor for this strategy. 
Further, the development of large HIV/AIDS cohorts in 
Africa and Asia suitable for GWAS and genome sequence 
analyses will be welcome additions to the screening of 
variants for important clinically relevant ARGs [48-50].
Finally, genomics is but one of several players in AIDS 
research and there are some extremely promising 
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developments outside our ﬁeld that must be mentioned. 
First, it is now well demonstrated that circumcision is a 
powerful protective aspect of HIV acquisition that is 
being implemented widely in the developing world to 
decrease the spread of HIV [66,67]. Second, three recent 
clinical trials have demonstrated a powerful near absolute 
protection against HIV infection among high-risk gay 
men and heterosexuals who took a single daily combi-
nation anti-retroviral pill (such pre-emptive treatment 
strategies are termed pre-exposure prophylaxis (PrEP)) 
[68,69]. In a large global cohort of 2,499 men who have 
sex with men, those treated with Truvada (a combination 
of two anti-retroviral agents, tenofovir and emtricitabine) 
showed a 48% reduction in HIV acquisition; this jumped 
to 95% protection when only those whose drug-taking 
compliance was 100% were considered [68]. Similar 
results were observed in an African trial where PrEP-
treated heterosexual at-risk women were studied [69]. 
Anti-retroviral microbicides are also making progress: 
two recent trials demonstrated 80% reduction in trans-
mission among compliant study participants [70]. Last, in 
what may be his greatest legacy, former US President 
George W. Bush established the President’s Emergency 
Plan for AIDS Relief (PEPFAR) in 2002, oﬀering 
US$15 billion in federal aid for treatment of HIV-infected 
people across the developing world. He added 
US$48 billion to the program in 2008. In 2002 there were 
less than 300,000 people on HAART in the developing 
world but today, thanks to PEPFAR, there are 6.6 million 
people on HAART. President Obama has continued 
PEPFAR funding and there is now tangible hope for 
slowing the spread of this contagion through education, 
treatment and research. By interdisciplinary application 
of important advances, the real dream is to one day see a 
generation of people that are free from AIDS.
Abbreviations
ARG: AIDS restriction gene; CCR5: C-C chemokine receptor; CHAVI: Center 
for HIV/AIDS Vaccine Immunology; GVHD: graft versus host disease; GWAS: 
genome-wide association study; HAART: highly active anti-retroviral therapy; 
HDF: HIV dependency factor; LD: linkage disequilibrium; NEMP: nuclear 
encoded mitochondrial protein; PEPFAR: President’s Emergency Plan for AIDS 
Relief; PrEP: pre-exposure prophylaxis; SNP: single nucleotide polymorphism; 
WNV, West Nile virus.
Author details
1Theodosius Dobzhansky Center for Genome Bioinformatics, 41A Sredniy 
Avenue, St Petersburg State University, St Petersburg, 199034, Russia. 
2Department of Biology, Shepherd University, P.O. Box 5000, Shepherdstown, 
West Virginia 25443-5000, USA.
Published: 31 January 2013
References
1. Pneumocystis pneumonia – Los Angeles. MMWR Morb Mortal Wkly Rep 
1981, 30:250–252.
2. Kaposi’s sarcoma and pneumocystis pneumonia among homosexual 
men – New York City and California. MMWR Morb Mortal Wkly Rep 1981, 
30:305–308.
3. World Health Organization. Global Health Observatory Data Repository. 
Life Expectancy [http://apps.who.int/ghodata/?vid=710%5D]
4. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, 
Dewar K, Doyle M, FitzHugh W, Funke R, Gage D, Harris K, Heaford A, Howland 
J, Kann L, Lehoczky J, LeVine R, McEwan P, McKernan K, Meldrim J, Mesirov JP, 
Miranda C, Morris W, Naylor J, Raymond C, Rosetti M, Santos R, Sheridan A, 
Sougnez C, et al.: Initial sequencing and analysis of the human genome. 
Nature 2001, 409:860–921.
5. An P, Winkler CA: Host genes associated with HIV/AIDS: advances in gene 
discovery. Trends Genet 2010, 26:119–31.
6. Carrington M, O’Brien SJ: The influence of HLA genotype on AIDS. Ann Rev 
Med 2003, 54:535–551.
7. Hutcheson H, Lautenberger J, Nelson G, Pontuis JJ, Kessing BD, Smith MW, 
Johonson R, Stephens R, Phair J, Goedert J, Donfield S, O’Brien SJ: Detecting 
AIDS restriction genes: from candidate genes to genome-wide association 
discovery. Vaccine 2008, 26:2951–2965.
8 Fellay J, Shianna KV, Telenti A, Goldstein DB: Host genetics and HIV-1: 
The final phase? PLoS Pathog 2010, 6:e1001033.
9. Lederman MM, Alter G, Daskalakis DC, Rodriguez B, Sieg SF, Hardy G, Cho M, 
Anthony D, Harding C, Weinberg A, Silverman RH, Douek DC, Margolis L, 
Goldstein DB, Carrington M, Goedert JJ: Determinants of protection among 
high risk HIV seronegative persons – an overview. J Infect Dis 2010, 
202:333–338.
10. O’Brien SJ, Nelson GW: Human genes that limit AIDS. Nat Genet 2004, 
36:565–574.
11. Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, Weale M, Zhang K, 
Gumbs C, Castagna A, Cossarizza A, Cozzi-Lepri A, De Luca A, Easterbrook P, 
Francioli P, Mallal S, Martinez-Picado J, Miro JM, Obel N, Smith JP, Wyniger J, 
Descombes P, Antonarakis SE, Letvin NL, McMichael AJ, Haynes BF, Telenti A, 
Goldstein DB: A whole-genome association study of major determinants 
for host control of HIV-1. Science 2007, 317:944–947.
12. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, Goedert 
JJ, Buchbinder SP, Vittinghoff E, Gomperts E, Donfield S, Vlahov D, Kaslow R, 
Saah A, Rinaldo C, Detels R, O’Brien SJ: Genetic restriction of HIV-1 infection 
and progression to AIDS by a deletion allele of the CKR5 structural gene. 
Science 1996, 273:1856–1862.
13. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, Saragosti S, 
Lapoumeroulie C, Cognaux J, Forceille C, Muyldermans G, Verhofstede C, 
Burtonboy G, Georges M, Imai T, Rana S, Yi Y, Smyth RJ, Collman RG, Doms 
RW, Vassart G, Parmentier M: Resistance to HIV-1 infection in Caucasian 
individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. 
Nature 1996, 382:722–725.
14. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, MacDonald ME, 
Stuhlmann H, Koup RA, Landau NR: Homozygous defect in HIV-1 
coreceptor accounts for resistance of some multiply-exposed individuals 
to HIV-1 infection. Cell 1996, 86:367–377.
15 Dean M, Jacobson LP, McFarlane G, Margolick JB, Jenkins FJ, Howard OMZ, 
Dong HF, Goedert JJ, Buchbinder S, Gomperts E, Vlahov D, Oppenheim JJ, 
O’Brien SJ, Carrington M: Reduced risk of AIDS lymphoma in individuals 
heterozygous for the CCR5 delta32 mutation. Cancer Res 1996, 
59:3561–3564.
16 Hendrickson SL, Jacobson LP, Nelson G, Phair JP, Johnson R, Margolick JB, 
Detels R, Rinaldo C, O’Brien SJ: Host genetic influences on highly active 
antiretroviral therapy efficacy and AIDS-free survival. J Acquir Immune Defic 
Syndr 2008, 48:263–271.
17. Murphy PM: International Union of Pharmacology. XXX. Update on 
chemokine receptor nomenclature. Pharmacol Rev 2002, 54:227–229.
18. O’Brien SJ, Dean M: In search of AIDS-resistance genes. Sci Am 1997, 
277:44–51.
19. Manfredi R, Sabbatani S: A novel antiretroviral class (fusion inhibitors) in 
the management of HIV infection. Present features and future 
perspectives of enfuvirtide (T-20). Curr Med Chem J 2006, 13:2369–2384.
20. Aquaro S, D’Arrigo R, Svicher V, Perri GD, Caputo SL, Visco-Comandini U, 
Santoro M, Bertoli A, Mazzotta F, Bonora S, Tozzi V, Bellagamba R, Zaccarelli M, 
Narciso P, Antinori A, Perno CF: Specific mutations in HIV-1 gp41 are 
associated with immunological success in HIV-1-infected patients 
receiving enfuvirtide treatment. J Antimicrob Chemother 2006, 58:714–722.
21. Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, Mori J, Rickett G, 
Smith-Burchnell C, Napier C, Webster R, Armour D, Price D, Stammen B, Wood 
A, Perros M: Maraviroc (UK-427,857), a potent, orally bioavailable, and 
selective small-molecule inhibitor of chemokine receptor CCR5 with 
broad-spectrum anti-human immunodeficiency virus type 1 activity. 
O’Brien and Hendrickson Genome Biology 2013, 14:201 
http://genomebiology.com/2013/14/1/201
Page 10 of 13
Antimicrob Agents Chemother 2005, 49:4721–4732.
22. Cohen J: The emerging race to cure HIV infections. Science 2011, 
332:784–789.
23. Hutter G, Nowak D, Mossner M, Ganepola S, Mussig A, Allers A, Schneider T, 
Hofmann J, Kucherer C, Blau O, Blau I, Hofmann WK, Thiel E: Long-term 
control of HIV by CCR5 delta32/delta32 stem-cell transplantation. 
New Engl J Med 2009, 360:692–698.
24. Allers K, Hütter G, Hofmann J, Loddenkemper C, Rieger K, Thiel E, Schneider T: 
Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell 
transplantation. Blood 2011, 117:2791–2799.
25. June C, Levine B: Blocking HIV’s attack. Sci Am 2012, 3:54–59.
26 Reshef R, Luger SM, Hexner EO, Loren AW, Frey NV, Nasta SD, Goldstein SC, 
Stadtmauer EA, Smith J, Bailey S, Mick R, Heitjan DF, Emerson SG, Hoxie JA, 
Vonderheide RH, Porter DL: Blockade of lymphocyte chemotaxis in visceral 
graft-versus-host disease. N Engl J Med 2012, 367:135–145.
27. Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomažič J, Jägel-Guedes 
E, Rugina S, Kozyrev O, Flores Cid J, Hay P, Nolan D, Hughes S, Hughes A, Ryan 
S, Fitch N, Thorborn D, Benbow A: HLA-B*5701 screening for 
hypersensitivity to abacavir. New Engl J Med 2008, 358:568–579.
28. Martin MP, Gao X, Lee HL, Nelson G, Detels R, Goedert JJ, Buchbinder S, Hoots 
K, Vlahov D, Trowsdale J, Wilson M, O’Brien SJ, Carrington M: Epistatic 
interaction between KIR3DS1 and HLA-B delays the progression to AIDS. 
Nat Genet 2002, 31:429–434.
29. Martin MP, Qi Y, Gao XJ, Brown EE, Phair J, Goedert JJ, Buchbinder S, Kirk G D, 
O’Brien SJ, Parham P, McVica EW, Carrington M: Innate partnership of HLA-B 
and KIR3DL1 subtypes against HIV-1. Nat Genet 2007, 39:733–740.
30. Kopp JB, Smith MW, Nelson GW, Johnson RC, Freedman BI, Bowden DW, 
Oleksyk T, McKenzie LM, Kajiyama H, Ahuja TS, Berns JS, Briggs W, Cho ME, 
Dart RA, Kimmel PL, Korbet SM, Michel DM, Mokrzycki MH, Schelling JR, 
Simon E, Trachtman H, Vlahov D, Winkler CA: MYH9 is a major-effect risk 
gene for focal segmental glomerulosclerosis. Nat Genet 2008, 40:1175–84.
31. Kao WH, Klag MJ, Meoni LA, Reich D, Berthier-Schaad Y, Li M, Coresh J, 
Patterson N, Tandon A, Powe NR, Fink NE, Sadler JH, Weir MR, Abboud HE, 
Adler SG, Divers J, Iyengar SK, Freedman BI, Kimmel PL, Knowler WC, Kohn OF, 
Kramp K, Leehey DJ, Nicholas SB, Pahl MV, Schelling JR, Sedor JR, Thornley-
Brown D, Winkler CA, Smith MW, Parekh RS, Family Investigation of 
Nephropathy and Diabetes Research Group: MYH9 is associated with 
nondiabetic end-stage renal disease in African Americans. Nat Gen 2008, 
40:1185–1192.
32. Dalmasso C, Carpentier W, Meyer L, Rouzioux C, Goujard C, Chaix ML, 
Lambotte O, Avettand-Fenoel V, Le Clerc S, de Senneville LD, Deveau 
C,Boufassa F, Debré P, Delfraissy JF, Broet P, Theodorou I, ANRS Genome Wide 
Association 01: Distinct genetic loci control plasma HIV-RNA and cellular 
HIV-DNA levels in HIV-1 infection. The ANRS Genome Wide Association 01 
study. PloS One 2008, 3:e3907.
33. Fellay J, Ge D, Shianna KV, Colombo S, Ledergerber B, Cirulli ET, Urban TJ, 
Zhang K, Gumbs CE, Smith JP, Castagna A, Cozzi-Lepri A, De Luca A, 
Easterbrook P, Günthard HF, Mallal S, Mussini C, Dalmau J, Martinez-Picado J, 
Miro JM, Obel N, Wolinsky SM, Martinson JJ, Detels R, Margolick JB, Jacobson 
LP, Descombes P, Antonarakis SE, Beckmann JS, O’Brien SJ, et al.: Common 
genetic variation and the control of HIV-1 in humans. PLoS Genet 2009, 
5:e1000791.
34. Le Clerc S, Limou S, Coulonges C, Carpentier W, Dina C, Taing L, Delaneau O, 
Labib T, Sladek R; ANRS Genomic Group, Deveau C, Guillemain 
H,Ratsimandresy R, Montes M, Spadoni JL, Therwath A, Schächter F, Matsuda 
F, Gut I, Lelièvre JD, Lévy Y, Froguel P, Delfraissy JF, Hercberg S, Zagury JF: 
Genome wide association study of a rapid progression cohort identifies 
new susceptibility alleles for AIDS (ANRS Genomewide Association Study 
03). J Infect Dis 2009, 200:1194–1201.
35. International HIV Controllers Study, Pereyra F, Jia X, McLaren PJ, Telenti A, de 
Bakker PI, Walker BD, Ripke S, Brumme CJ, Pulit SL, Carrington M, Kadie CM, 
Carlson JM, Heckerman D, Graham RR, Plenge RM, Deeks SG, Gianniny L, 
Crawford G, Sullivan J, Gonzalez E, Davies L, Camargo A, Moore JM, Beattie N, 
Gupta S, Crenshaw A, Burtt NP, Guiducci C, Gupta N, et al.: The major genetic 
determinants of HIV-1 control affect HLA class I peptide presentation. 
Science 2010, 330:1551–1557.
36. Limou S, Le Clerc S, Coulonges C, Carpentier W, Dina C, Delaneau O, Labib T, 
Taing L, Sladek R, Deveau C, Ratsimandresy R, Montes M, Spadoni JL,Lelièvre 
JD, Lévy Y, Therwath A, Schächter F, Matsuda F, Gut I, Froguel P, Delfraissy JF, 
Hercberg S, Zagury JF; ANRS Genomic Group: Genome wide association 
study of an AIDS-nonprogression cohort emphasizes the role played by 
HLA genes (ANRS Genomewide Association Study 02). J Infect Dis 2009, 
199:419–426.
37. Herbeck JT, Gottlieb GS, Winkler CA, Nelson GW, An P, Maust BS, Wong KG, 
Troyer JL, Goedert JJ, Kessing BD, Detels R, Wolinsky SM, Martinson J, 
Buchbinder S, Kirk GD, Jacobson LP, Margolick JB, Kaslow RA, O’Brien SJ, 
Mullins JI: Multistage genome wide association study identifies a locus at 
1q41 associated with rate of HIV-1 disease progression to clinical AIDS. 
J Infect Dis 2010, 201:618–626.
38. Limou S, Coulonges C, Herbeck JT, van Manen D, An P, Le Clerc S, Delaneau O, 
Diop G, Taing L, Montes M, van’t Wout AB, Gottlieb GS, Therwath A, Rouzioux 
C, Delfraissy JF, Lelièvre JD, Lévy Y, Hercberg S, Dina C, Phair J, Donfield S, 
Goedert JJ, Buchbinder S, Estaquier J, Schächter F, Gut I, Froguel P, Mullins JI, 
Schuitemaker H, Winkler C, Zagury JF: Multiple-cohort genetic association 
study reveals CXCR6 as a new chemokine receptor involved in long-term 
nonprogression to AIDS. J Infect Dis 2010, 202:908–915.
39. Pelak K, Goldstein DB, Walley NM, Fellay J, Ge D, Shianna KV, Gumbs C, Gao X, 
Maia JM, Cronin KD, Hussain SK, Carrington M, Michael NL, Weintrob AC, 
Infectious Disease Clinical Research Program HIV Working Group, National 
Institute of Allergy and Infectious Diseases Center for HIV/AIDS Vaccine 
Immunology (CHAVI): Host determinants of HIV-1 control in African 
Americans. J Infect Dis 2010, 201:1141–1149.
40. Troyer JL, Nelson GW, Lautenberger JA, Chinn L, McIntosh C, Johnson RC, 
Sezgin E, Kessing B, Malasky M, Hendrickson SL, Li G, Pontius J, Tang M, An P, 
Winkler CA, Limou S, Le Clerc S, Delaneau O, Zagury JF, Schuitemaker H, van 
Manen D, Bream JH, Gomperts ED, Buchbinder S, Goedert JJ, Kirk GD, O’Brien 
SJ: Genome-wide association study implicates PARD3B-based AIDS 
restriction. J Infect Dis 2011, 203:1491–502.
41. Limou S, Delaneau O, van Manen D, An P, Sezgin E, Le Clerc S, Coulonges C, 
Troyer JL, Veldink JH, van den Berg LH, Spadoni JL, Taing L, Labib T, Montes M, 
Delfraissy JF, Schachter F, O’Brien SJ, Buchbinder S, van Natta ML, Jabs DA, 
Froguel P, Schuitemaker H, Winkler CA, Zagury JF: Multicohort genomewide 
association study reveals a new signal of protection against HIV-1 
acquisition. J Infect Dis 2012, 205:1155–1162.
42. Goldstein DB: Common genetic variation and human traits. New Engl J Med 
2009, 360:1696–1698.
43. Cirulli ET, Goldstein DB: Uncovering the roles of rare variants in common 
disease through whole-genome sequencing. Nat Rev Genet 2010, 
11:415–425.
44. Kohjima M, Noda Y, Takeya R, Saito N, Takeuchi K, Sumimoto H: PAR3beta, a 
novel homologue of the cell polarity protein PAR3, localizes to tight 
junctions. Biochem Biophys Res Comm 2002, 299:641–646.
45. Abraham S, Sawaya BE, Safak M, Batuman O, Khalili K, Amini S: Regulation of 
MCP-1 gene transcription by Smads and HIV-1 Tat inhuman glial cells. 
Virology 2003, 309:196–202.
46.  O’Brien SJ: Stewardship of human biospecimens, DNA, genotype, and 
clinical data in the GWAS era. Ann Rev Genomics Hum Genet 2009, 
10:193–209.
47. McLaren PJ, Zagury JF, Fellay J: Joining forces in HIV host genomics: the 
International HIV Acquisition Consortium. CROI 2012, abstract #295.
48. Petrovski S, Fellay J, Shianna KV, Carpenetti N, Kumwenda J, Kamanga G, 
Kamwendo DD, Letvin NL, McMichael AJ, Haynes BF, Cohen MS, Goldstein 
DB, Center for HIV/AIDS Vaccine Immunology: Common human genetic 
variants and HIV-1 susceptibility: a genome-wide survey in a 
homogeneous African population. AIDS 2011, 25:513–518.
49.  Wester CW, Eden SK, Shepherd BE, Bussmann H, Novitsky V, Samuels DC, 
Hendrickson SL, Winkler CA, O’Brien SJ, Essex M, D’Aquila RT, Degruttola V, 
Marlink RG: Risk factors for symptomatic hyperlactatemia and lactic 
acidosis among combination antiretroviral therapy-treated adults in 
Botswana: results from a clinical trial. AIDS Res Hum Retroviruses 2012, 
28:759–765.
50.  Yu XF, Liu W, Chen J, Kong W, Liu B, Zhu Q, Liang F, McCutchan F, Piyasirisilp S, 
Lai S. Maintaining low HIV type 1 env genetic diversity among injection 
drug users infected with a B/C recombinant and CRF01_AE HIV type 1 in 
southern China. AIDS Res Hum Retroviruses 2002, 18:167–170.
51. Cirulli ET, Singh A, Shianna KV, Ge D, Smith JP, Maia JM, Heinzen EL, Goedert 
JJ, Goldstein DB, Center for HIV/AIDS Vaccine Immunology (CHAVI): 
Screening the human exome: a comparison of whole genome and whole 
transcriptome sequencing. Genome Biol 2010, 11:R57.
52. Hendrickson, SL, Lautenberger, J, Chinn, L, Phair, J, Goedert, JJ, Vlahov, D, 
Donfield, S. Buchbinder, SP, Troyer, J, O’Brien, SJ: Genetic variants in nuclear-
encoded mitochondrial genes influence AIDS progression. PLoS One 2010, 
O’Brien and Hendrickson Genome Biology 2013, 14:201 
http://genomebiology.com/2013/14/1/201
Page 11 of 13
5:e12862.
53. Pagliarini DJ, Calvo SE, Chang B, Sheth SA, Vafai SB, Ong SE, Walford GA, 
Sugiana C, Boneh A, Chen WK, Hill DE, Vidal M, Evans JG, Thorburn DR,Carr SA, 
Mootha VK: A mitochondrial protein compendium elucidates complex I 
disease biology. Cell 2008, 134:112–123.
54. LewisW, Dalakas MC: Mitochondrial toxicity of antiviral drugs. Nat Med 
1995, 1:417–422.
55. Hendrickson SL, Kingsley LA, Ruiz-Pesini E, Poole JC, Jacobson LP, Palella FJ, 
Bream JH, Wallace DC, O’Brien SJ: Mitochondrial DNA haplogroups 
influence lipoatrophy after highly active antiretroviral therapy. J Acquir 
Immune Defic Syndr 2009, 51:111–116.
56. Hendrickson SL, Hutcheson HB, Ruiz-Pesini E, Poole JC, Lautenberger J, Sezgin 
E, Kingsley L, Goedert JJ, Vlahov D, Donfield S, Wallace DC, O’Brien SJ: 
Mitochondrial DNA haplogroups influence AIDS progression. AIDS 2008, 
22:2429–2439.
57. Chinn LW, Tang M, Kessing BD, Lautenberger JA, Troyer JL, Malasky MJ, 
McIntosh C, Kirk GD, Wolinsky SM, Buchbinder SP, Gomperts ED, Goedert JJ, 
O’Brien SJ: Genetic associations of variants in genes encoding HIV-
dependency factors required for HIV-1 infection. J Infect Dis 2010, 
202:1836–1845.
58. Brass AL, Dykxhoorn DM, Benita Y, Yan N, Engelman A, Xavier RJ, Lieberman J, 
Elledge SJ: Identification of host proteins required for HIV infection 
through a functional genomic screen. Science 2008, 319:921–926.
59. König R, Zhou Y, Elleder D, Diamond TL, Bonamy GM, Irelan JT, Chiang CY, Tu 
BP, De Jesus PD, Lilley CE, Seidel S, Opaluch AM, Caldwell JS,Weitzman MD, 
Kuhen KL, Bandyopadhyay S, Ideker T, Orth AP, Miraglia LJ, Bushman FD, 
Young JA, Chanda SK: Global analysis of host-pathogen interactions that 
regulate early-stage HIV-1 replication. Cell 2008, 135:49–60.
60. Zhou H, Xu M, Huang Q, Gates AT, Zhang XD, Castle JC, Stec E, Ferrer M, 
Strulovici B, Hazuda DJ, Espeseth AS: Genome-scale RNAi screen for host 
factors required for HIV replication. Cell Host Microbe 2008, 4:495–504.
61. Yeung ML, Houzet L, Yedavalli VS, Jeang KT: A genome-wide short hairpin 
RNA screening of jurkat T-cells for human proteins contributing to 
productive HIV-1 replication. J Biol Chem 2009, 284:19463–19473.
62. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter 
H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, 
Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg 
RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, 
Papadopoulos N, Parmigiani G, et al.: An integrated genomic analysis of 
human glioblastoma multiforme. Science 2008, 321:1807–1812.
63. Gross S, Cairns RA, Minden MD, Driggers EM, Bittinger MA, Jang HG, Sasaki M, 
Jin S, Schenkein DP, Su SM, Dang L, Fantin VR, Mak TW: Cancer-associated 
metabolite 2-hydroxyglutarate accumulates in acute myelogenous 
leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med 
2010, 207:339–344.
64. Garber K: Oncometabolite? IDH1 discoveries raise possibility of new 
metabolism targets in brain cancers and leukemia. J Nat Cancer Inst 
102:926–928.
65 ENCODE Project Consortium, Bernstein BE, Birney E, Dunham I, Green ED, 
Gunter C, Snyder M: An integrated encyclopedia of DNA elements in the 
human genome. Nature 2012, 489:57–74.
66. Bailey RC, Moses S, Parker CB, Agot K, Maclean I, Krieger JN, Williams CF, 
Campbell RT, Ndinya-Achola JO: Male circumcision for HIV prevention in 
young men in Kisumu, Kenya: a randomised controlled trial. Lancet 2007, 
369:643–656.
67. Gray RH, Kigozi G, Serwadda D, Makumbi F, Watya S, Nalugoda F, Kiwanuka N, 
Moulton LH, Chaudhary MA, Chen MZ, Sewankambo NK, Wabwire-Mangen F, 
Bacon MC, Williams CF, Opendi P, Reynolds SJ, Laeyendecker O, Quinn TC, 
Wawer MJ: Male circumcision for HIV prevention in men in Rakai, Uganda: 
a randomised trial. Lancet 2007, 369:657–666.
68. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea P, 
Casapía M, Guanira-Carranza JV, Ramirez-Cardich ME, Montoya-Herrera O, 
Fernández T, Veloso VG, Buchbinder SP, Chariyalertsak S, Schechter M, Bekker 
LG, Mayer KH, Kallás EG, Amico KR: Preexposure chemoprophylaxis for HIV 
prevention in men who have sex with men. New Engl J Med 2010, 
363:2587–2599.
69. Safety and Effectiveness of Tenofovir 1% Gel, Tenofovir Disproxil Fumarate, 
and Emtricitabine/Tenofovir Disoproxil Fumarate Tablets in Preventing HIV 
in Women. Clinical trial [http://clinicaltrials.gov/ct2/show/NCT00705679]
70. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor 
LE, Kharsany AB, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, 
Arulappan N, Mlotshwa M, Morris L, Taylor D, CAPRISA 004 Trial Group: 
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for 
the prevention of HIV infection in women. Science 2010, 329:1168–1174.
71. Carrington M, Kissner T, Gerrard B, Ivanov S, O’Brien SJ, Dean, M: Novel alleles 
of the chemokine-receptor gene CCR5. Am J Hum Genet 1997, 
61:1261–1267.
72. Stephens JC, Dating the origin of the CCR5-Δ32 AIDS resistance gene allele 
by the coalescence of haplotypes. Am J Hum Genet 1998, 62:1507–1515.
73. Bamshad MJ, Mummidi S, Gonzalez E, Ahuja SS, Dunn DM, Watkins WS, 
Wooding S, Stone AC, Jorde LB, Weiss RB, Ahuja SK: A strong signature of 
balancing selection in the 5’ cis-regulatory region of CCR5. Proceed Nat 
Acad Sci U S A 2002, 99:10539–10544.
74. Sabeti PC, Walsh E, Schaffner S, Varilly P, Fry B, Cullen M, Mikkelsen T, Roy J, 
Patterson N, Cooper R, Altshuler D, Lander ES: The case for selection at 
CCR5Δ32. PloS Biol 2005, 3:1963–1969.
75.  Elvin SJ, Williamson ED, Scott JC, Smith JN, Pérez De Lema G, Chilla S, 
Clapham P, Pfeffer K, Schlöndorff D, Luckow B: Evolutionary genetics: 
Ambiguous role of CCR5 in Y. pestis infection. Nature 2004, 430:417–424.
76. O’Brien SJ: Tears of the Cheetah and Other Tales from the Genetic Frontier. 
St Martin’s Press: New York; 2003.
77. Glass WG, Lim JK, Cholera R, Pletnev AG, Gao JL, Murphy PM: Chemokine 
receptor CCR5 promotes leukocyte trafficking to the brain and survival in 
West Nile virus infection. J Exp Med 2005, 202:1087–98.
78. Glass WG, McDermott DH, Lim JK, Lekhong S, Yu SF, Frank WA, Pape J, 
Cheshier RC, Murphy PM: CCR5 deficiency increases risk of symptomatic 
West Nile virus infection. J Exp Med 2006, 203:35–40.
79. O’Brien SJ, Moore J: The effect of genetic variation in chemokines and their 
receptors on HIV transmission and progression to AIDS. Immunol Rev 2000, 
177:99–111.
80. Smith MW, Dean M, Carrington M, Winkler C, Huttley GA, Lomb DA, Goedert 
JJ, O’Brien TR, Jacobson LP, Kaslow R, Buchbinder S, Vittinghoff E, Vlahov D, 
Hoots K, Hilgartner MW, O’Brien SJ: Contrasting genetic influence of CCR2 
and CCR5 variants on HIV-1 infection and disease progression. Science 
1997, 277:959–965.
81. Martin MP, Dean M, Smith MW, Winkler C, Gerrard B, Michael NL, Lee B, Doms 
RW, Margolick J, Buchbinder S, Goedert JJ, O’Brien TR, Hilgartner MW, Vlahov 
D, O’Brien SJ, Carrington M: Genetic acceleration of AIDS progression by a 
promoter variant of CCR5. Science 1998, 282:1907–1911.
82. Winkler C, Modi W, Smith MW, Nelson GW, Wu X, Carrington M, Dean M, 
Honjo T, Tashiro K, Yabe D, Buchbinder S, Vittinghoff E, Goedert JJ, O’Brien TR, 
Jacobson LP, Detels R, Donfield S, Willoughby A, Gomperts E, Vlahov D, Phair 
J, O’Brien SJ: Genetic restriction of AIDS pathogenesis by an SDF-1 
chemokine gene variant. Science 1998, 279:389–393.
83. Carrington M, Nelson GW, Martin MP, Kissner T, Vlahov D, Goedert JJ, Kaslow 
R, Buchbinder S, Hoots K, O’Brien SJ: HLA and HIV-1: Heterozygote 
advantage and B*35-Cw*04 disadvantage. Science 1999, 283:1748–1752.
84. Shin HD, Winkler C, Stephens JC, Bream J, Young H, Goedert JJ, O’Brien TR, 
Vlahov D, Buchbinder S, Giorgi J, Rinaldo C, Donfield S, Willoughby A, O’Brien 
SJ, Smith MW: Genetic restriction of HIV-1 pathogenesis to AIDS by 
promoter alleles of IL10. Proc Natl Acad Sci U S A 2000, 97:14467–14472
85. Gao X, Nelson GW, Karacki P, Martin MP, Phair J, Kaslow R, Goedert JJ, 
Buchbinder S, Hoots K, Vlahov D, O’Brien SJ, Carrington M: Effect of a single 
amino acid change in MHC class I molecules on the rate of progression to 
AIDS. New Engl J Med 2001, 344:1668–1675.
86. An P, Nelson GW, Wang L, Donfield S, Goedert JJ, Phair J, Vlahov D, 
Buchbinder S, Farrar WL, Modi W, O’Brien SJ, Winkler CA: Modulating 
influence on HIV/AIDS by interacting RANTES gene variants. Proc Natl Acad 
Sci U S A 2002, 99:10002–10007.
87. Modi WS, Goedert JJ, Strathdee S, Buchbinder S, Detels R, Donfield S, O’Brien 
SJ, Winkler C: MCP-1-MCP-3-Eotaxin gene cluster influences HIV-1 
transmission. AIDS 2003, 17:2357–2365.
88. Carrington M, O’Brien SJ: The influence of HLA genotype on AIDS. Ann Rev 
Med 2003, 54:535–551.
89. An P, Vlahov D, Margolick JB, Phair J, O’Brien TR, Lautenberger J, O’Brien SJ, 
Winkler CA: A tumor necrosis factor-alpha-inducible promoter variant of 
interferon-gamma accelerates CD4+ T cell depletion in human 
immunodeficiency virus-1-infected individuals. J Infect Dis 2003, 
188:228–231.
90. Duggal P, An P, Beaty TH, Strathdee SA, Farzadegan H, Markham RB, Johnson 
L, O’Brien SJ, Vlahov D, Winkler CA: Genetic influence of CXCR6 chemokine 
receptor alleles on PCP-mediated AIDS progression among African-
O’Brien and Hendrickson Genome Biology 2013, 14:201 
http://genomebiology.com/2013/14/1/201
Page 12 of 13
Americans. Genes Immun 2003, 4:245–250.
91. An P, Bleiber G, Duggal P, Nelson G, May M, Mangeat B, Alobwede I, Trono D, 
Vlahov D, Donfield S, Goedert JJ, Phair J, Buchbinder S, O’Brien SJ, Telenti A, 
Winkler CA: APOBEC3G genetic variants and their influence on the 
progression to AIDS. J Virol 2004, 78:11070–11076.
92. Martin MP, Lederman MM, Hutcheson HB, Goedert JJ, Nelson GW, van Kooyk 
Y, Detels R, Buchbinder S, Hoots K, Vlahov D, O’Brien SJ, Carrington M: 
Association of DC SIGN promoter polymorphisms with increased risk for 
parenteral but not mucosal acquisition of HIV-1 infection. J Virol 2003, 
78:14053–14056.
93. Gao X, Bashirova A, Iversen AK, Phair J, Goedert JJ, Buchbinder S, Hoots K, 
Vlahov D, Altfeld M, O’Brien SJ, Carrington M: AIDS restriction HLA allotypes 
target distinct intervals of HIV-1 pathogenesis. Nat Med 2006, 
11:1290–1292.
94. Bashirova AA, Bleiber G, Qi Y, Hutcheson H, Yamashita T, Johnson RC, Cheng J, 
Alter G, Goedert JJ, Buchbinder S, Hoots K, Vlahov D, May M, Maldarelli F, 
Jacobson L, O’Brien SJ, Telenti A, Carrington M: Consistent effects of TSG101 
genetic variability on multiple outcomes of exposure to human 
immunodeficiency virus type 1. J Virol 2006, 80:6757–6763.
95. Javanbakht H, An P, Gold B, Petersen DC, O’Huigin C, Nelson GW, O’Brien SJ, 
Kirk GD, Detels R, Buchbinder S, Donfield S, Shulenin S, Song B, Perron MJ, 
Stremlau M, Sodroski J, Dean M, Winkler C: Effects of human TRIM5alpha 
polymorphisms on antiretroviral function and susceptibility to human 
immunodeficiency virus infection. Virology 2006, 354:15–27.
96. An P, Duggal P, Wang LH, O’Brien SJ, Donfield S, Goedert JJ, Phair J, 
Buchbinder S, Kirk GD, Winkler CA: Polymorphisms of CUL5 area ssociated 
with CD4+ T cell loss in HIV-1 infected individuals. PLoS Genet 2007, 3:e19.
97. An P, Wang LH, Hutcheson-Dilks H, Nelson G, Donfield S, Goedert JJ, Rinaldo 
CR, Buchbinder S, Kirk GD, O’Brien SJ, Winkler CA: Regulatory 
polymorphisms in the cyclophilin A gene, PPIA accelerate progression to 
AIDS. PLoS Pathog 2007, 3:849–857.
98. Welzel TM, Gao X, Pfeiffer RM, Martin MP, O’Brien SJ, Goedert JJ, Carrington M, 
O’Brien TR: HLA Bw4 alleles and HIV-1 transmission in heterosexual 
couples. AIDS 2007, 21:225–229.
99. Hendrickson SL, Jabs DA, Van Natta M, Lewis RA, Wallace DC, O’Brien SJ: 
Mitochondrial haplogroups are associated with risk of neuroretinal 
disorder in HIV-positive patients. J Acquir Immune Defic Syndr 2010, 
53:451–455.
100. An P, Johnson R, Phair J, Kirk GD, Yu XF, Donfield S, Buchbinder S, Goedert JJ, 
Winkler CA: APOBEC3B deletion and risk of HIV-1 acquisition. J Infect Dis 
2008, 200:1054–1058.
101. O’Brien SJ, Nelson GW, Winkler CA, Smith MW: Polygenic and multifactorial 
disease gene association in man: lessons from AIDS. Ann Rev Genet 2000, 
34:563–591.
doi:10.1186/gb-2013-14-1-201
Cite this article as: O’Brien SJ, Hendrickson SL: Host genomic influences on 
HIV/AIDS. Genome Biology 2013, 14:201.
O’Brien and Hendrickson Genome Biology 2013, 14:201 
http://genomebiology.com/2013/14/1/201
Page 13 of 13
